Loading clinical trials...
Discover 10,048 clinical trials near Portland, Oregon. Find research studies in your area.
Browse by condition:
Showing 5761-5780 of 10,048 trials
NCT00948428
At the end of the study, safety and efficacy outcome measures will be compared to determine a) if dosing with Generic Imiquimod cream, 5% is therapeutically equivalent to the currently marketed Aldara (imiquimod) cream, 5% and b) if both imiquimod 5% creams are superior in comparison to the Vehicle cream.
NCT01516957
The study will examine the safety and effectiveness of AMG 827 for the treatment of psoriatic arthritis
NCT01104818
National estimates indicate that roughly 70% of children in foster care have one or more siblings also in care. Exact percentages vary by state, but several data sources suggest that about 50% of early adolescent foster youth are placed apart from one or more of their siblings. Relationships between these siblings may be critical in providing them a sense of connection and emotional continuity as they are removed from much that is familiar (e.g. their home, parents, and friends). Historically, efforts to strengthen ties of foster children with their families have focused on adults (e.g., biological parents, grandparents). Limited research exists on the relationships of siblings in foster care. The central aim of the proposed study is to evaluate the impact of the Sibling plus Parent Management Training (SPMT) intervention as compared to Parent Management Training-only (PMT) on key constructs of sibling relationship quality, mental health, academic success, and quality of life for youth in foster care. Conducted in partnership with the Oregon DHS Foster Care program, 240 sibling dyads and their foster parents will be enrolled in six cohorts. Siblings may live together or in separate placements. Dyads will consist of (1) a target youth in care that is 11-15 years of age, and (2) a younger sibling in care who is 7-15 years of age and within 4 years of age of the target youth. Sibling dyads will be matched as living together or living apart; the matched dyads will be randomly assigned to either the SPMT or PMT-only group, with all study-enrolled foster parents receiving PMT intervention components. The SPMT intervention includes a sibling component as well as foster parent PMT. The sibling intervention component includes eight cognitive behavioral sessions of skills learning/practice, and four community activities planned by siblings with their interventionist coaches. For foster parents, there is a 4-session PMT curriculum emphasizing skills learning and practice with their study-enrolled foster child. Additional sessions are available to foster parents on request. Foster parents will also be able to access and troubleshoot PMT materials and strategies via weekly staff check-in calls, and the project website. Major wave assessments will be conducted at baseline, intervention termination (6 months), follow-along1 (6-month post-intervention) and follow-along2 (12-month post-intervention). Brief, bi-monthly phone interviews for youth and foster parents will collect service utilization data and global ratings of outcome constructs for use in growth-modeling analyses. Hierarchical Linear Models (HLM) and multiple regression analyses will be used to test (1) the prediction that SPMT siblings will improve more than PMT siblings on key outcomes, and (2) whether intervention efficacy varies by sibling placement (together vs. apart) and participant characteristics such as race, gender, and disability
NCT02113085
The purpose of the study is to implement a full-scale efficacy trial of the My Life program. Conducted in partnership with the Oregon DHS Foster Care Program, the impact of the intervention will be being evaluated with a randomized experimental longitudinal design. Two hundred and ten youth, ages 16.5-17.5, will be enrolled in 3 waves, and randomly assigned to either a comparison group that receives typical foster care services or to a treatment group that participates in the key elements of the model, including instruction in self-determination skills, support in leading their own coordinated inter-agency transition planning meetings, and participation in workshops with mentors. Outcomes, including youth self-determination, quality of life, employment, mental health, educational achievement and independent living, are assessed pre-intervention, at the conclusion of intervention, and at 12 months post-intervention. The proposed study will provide important information on the efficacy of the model for all youth exiting the foster care system, yielding unequivocal data on whether enhanced self-determination mediates, at least partially, various outcome areas, including mental health, educational achievement, employment, independent living, and quality of life; evaluating the effect of special education status, gender, and race as moderating influences on the impact of the intervention. Foster care experiences, such as trauma and placement instability, will be considered as covariates; direct effects of the intervention on these key foster care experiences will also be explored.
NCT01610284
This study was a multi-center, randomized, double-blind, placebo controlled Phase III study to determine the efficacy and safety of treatment with buparlisib plus fulvestrant versus fulvestrant plus placebo in postmenopausal women with hormone Receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative), locally advanced or metastatic breast cancer (MBC) whose disease has progressed on or after aromatase inhibitor (AI) treatment.
NCT01068769
The purpose of this research study is to determine the safety and activity of regorafenib in participants with advanced gastrointestinal stromal tumor (GIST) if the standard approved therapies, imatinib and sunitinib, have failed to control the disease. Regorafenib is a drug that blocks abnormally active signaling enzymes called "tyrosine kinases" which are important to the growth of GIST. This "tyrosine kinase inhibition" is similar to the way that both imatinib and sunitinib work; however, regorafenib blocks certain additional signaling pathways that are not blocked by imatinib or sunitinib. Regorafenib has been not been tested in GIST participants before this research study.
NCT01797562
The objective of the study was to evaluate the diagnostic performance and safety of T.R.U.E. Test allergens in pediatric subjects aged 6-17 years old. In total, 11 allergens were evaluated; 7 new allergens on panels 2.2 and 3.2 and 4 previously approved allergens for which changes were made to dose and excipient.
NCT02431806
The purpose of this study is to evaluate the efficacy, safety, and tolerability of levomilnacipran ER relative to placebo in adolescent outpatients (12-17 years) with Major Depressive Disorder (MDD). In addition, the study is designed to obtain pharmacokinetics (PK) data to guide dose selection for future pediatric studies of levomilnacipran.
NCT02516046
This study is designed to test the relationship between ante-mortem flortaucipir Positron Emission Tomography (PET) imaging and tau neurofibrillary pathology associated with Alzheimer's disease (AD), as measured at autopsy.
NCT00959959
The purpose of this study is to determine whether TOK-001 is safe and shows biological effect in the treatment of castration resistant prostate cancer (CRPC).
NCT03036124
The purpose of this study is to evaluate the effect of dapagliflozin on the incidence of worsening heart failure or cardiovascular death in patients with chronic heart failure with reduced ejection fraction
NCT01721733
The purpose of this study is to evaluate the effects of EPI-743 in children with Leigh syndrome on disease severity, neuromuscular function, respiratory function, disease morbidity and mortality and disease associated biomarkers.
NCT03560518
The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) and 900 milligrams (mg) of Rapastinel, compared to placebo in participants with major depressive disorder (MDD).
NCT03482882
The purpose of this study is to assess the efficacy of pimavanserin for the treatment of depression in adults with Parkinson's disease.
NCT02757976
This trial will compare two strategies for patients with Heart Failure, Left Ventricular systolic dysfunction, and intermediate QRS durations. The control group is conventional CRT. The experimental group is LVendo CRT
NCT00799266
This study was designed to evaluate the efficacy and safety of zoledronic acid compared to placebo in osteoporotic children treated with glucocorticoids
NCT02644668
This study will evaluate the pharmacodynamic (PD) effect of CK-2127107 (hereafter referred to as reldesemtiv) versus placebo on measures of skeletal muscle function or fatigability in patients with Type II, III, or IV spinal muscular atrophy (SMA).
NCT02995265
To determine the effect of using a robotic exoskeleton to allow walking practice after stroke, compared to usual physiotherapy care, on recovery of walking ability and secondary outcomes.
NCT03241810
This study is a multi-center, randomized, double-blind, placebo-controlled, Phase 2 study in postmenopausal women with heregulin positive, hormone receptor positive, HER2 negative metastatic, unresectable breast cancer.
NCT02174848
Patients with PKAN will be treated with the iron chelator deferiprone for 18 months. Only patients who have completed the earlier study TIRCON2012V1 (NCT01741532), a double-blind placebo-controlled trial in which participants were randomized to receive either deferiprone or placebo for 18 months, are eligible to enroll.
